SCHEMBL7812435

SCHEMBL7812435

CC(C)(C)c1ccncc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC1 P19801 2/20 0.43
AOC3 Q16853 2/20 0.43
GAA P10253 2/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM6B O15054 1/20 0.41
KDM4A O75164 1/20 0.41
THRB P10828 1/20 0.41
KDM4D Q6B0I6 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GLA P06280 1/20 0.40
LMNA P02545 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31505115 1.00 AOC1 (0.43) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL3379818 0.83 ALDH1A1 (0.42) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL293749 0.82 GAA (0.46) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL23181516 0.79 KDM4E (0.47) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL1705592 0.78 KIF11 (0.39) GAAALDH1A1TDP1KIF11ALOX5
SCHEMBL971004 0.77 AOC1 (0.43) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL30905972 0.77 AOC1 (0.43) AOC1AOC3GAAALDH1A1MAPT
SCHEMBL20576799 0.76 KIF11 (0.38) ALDH1A1MAPTKDM4ECYP2D6CYP1A2
SCHEMBL682267 0.74 TRPA1 (0.37) ALDH1A1TDP1CYP2D6CYP1A2CYP3A4
SCHEMBL21341323 0.73 KIF11 (0.35) KIF11ALOX5PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260107629-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-04-16 US disclosed
EP-3880666-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-06-28 EP disclosed
US-20230008433-A1 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. 2023-01-12 US disclosed
US-10766865-B2 PKM2 modulators and methods for their use SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2020-09-08 US disclosed
US-10472328-B2 PKM2 modulators and methods for their use TOLERO PHARMACEUTICALS, INC. (US) 2019-11-12 US disclosed
US-20190119219-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2019-04-25 US disclosed
US-9856257-B2 Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) SANOFI (FR) 2018-01-02 US disclosed
US-9849138-B2 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-12-26 US disclosed
US-9849138-B2 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-12-26 US disclosed
US-20160095866-A1 1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2016-04-07 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-8815845-B2 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-26 US disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20130079337-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-28 US disclosed
US-20120283229-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-11-08 US disclosed
US-20120270862-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-25 US disclosed
US-20120270862-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-25 US disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283229-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES ROCK1, ROCK2, GABRR1 AOC1 4703/4885AOC3 3445/4885GAA 2800/4885
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 AOC1 3351/4885AOC3 3563/4885GAA 780/4885
US-20260107629-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OXSR1, SCO2 AOC1 338/4885AOC3 247/4885GAA 4650/4885
US-20130079337-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, COQ8A, CYP1A2 AOC1 2903/4885AOC3 3014/4885GAA 1467/4885
US-10766865-B2 PKM2 modulators and methods for their use PDK1, PDK2, PKM AOC1 4727/4885AOC3 4720/4885GAA 2655/4885
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A AOC1 3063/4885AOC3 3009/4885GAA 1631/4885
US-20120270862-A1 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES ROCK1, ROCK2, GABRR1 AOC1 4438/4885AOC3 3301/4885GAA 2899/4885
US-20230008433-A1 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP AOC1 3894/4885AOC3 3113/4885GAA 1897/4885
US-20160095866-A1 1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties ROCK1, ROCK2, GABRR1 AOC1 4626/4885AOC3 3407/4885GAA 3108/4885
US-10472328-B2 PKM2 modulators and methods for their use PDK1, PDK2, PKM AOC1 4727/4885AOC3 4720/4885GAA 2655/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 AOC1 3351/4885AOC3 3563/4885GAA 780/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AOC1 532/4885AOC3 411/4885GAA 216/4885
US-20190119219-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM AOC1 4727/4885AOC3 4720/4885GAA 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.